BioSIM 抗人 TNFRSF17/CD269 抗体 (贝

BioSIM 抗人 TNFRSF17/CD269 抗体（贝兰妥单抗生物类似药，科研用途）

产品基本信息

• 英文名称：BioSIM anti-Human TNFRSF17/CD269 Antibody (Belantamab Biosimilar), Research Grade
• 中文名称：BioSIM 抗人 TNFRSF17/CD269 抗体（贝兰妥单抗生物类似药，科研用途）
• CAS号：2061894-48-0
• 供应商：InvivoCrown
• 产品货号：SIM0060-5mg
• 产品规格：5mg
• 产品类型：二抗

核心参数

• 来源宿主：Humanized（人源化）
• 反应性：Human（人源）
• 免疫原：请参考产品说明书

背景与研究价值

本产品为**非治疗性贝兰妥单抗生物类似药**，与靶向BCMA/CD269/TNFRSF17的治疗性人源化IgG1单克隆抗体共享可变区，适配科研场景需求。

BCMA（III型膜糖蛋白）具有明确的表达与功能特征：

• 表达分布：生理状态下存在于成熟血浆B细胞（正常淋巴组织）表面；病理状态下在多发性骨髓瘤（MM）细胞中呈高表达；
• 分子结合：可与APRIL结合（亲和力高于BAFF）；
• 信号调控：参与NF-κB/JNK-3通路，影响B细胞存活及体液免疫平衡。

治疗性Belantamab-mafodotin ADC可诱导ADCC效应及癌细胞凋亡，本产品因与治疗性抗体共享可变区，适合用于BCMA相关机制及多发性骨髓瘤的基础研究。

应用场景

本产品支持以下科研应用方向：

• ELISA：检测样本中BCMA抗原或抗体结合活性；
• FACS：分析细胞表面BCMA的表达水平及分布特征；
• Functional assay：评估抗体结合BCMA后的功能学影响；
• Research in vivo：动物模型水平的BCMA相关机制研究（需结合科研设计）。

储存建议

为保障产品稳定性，需遵循以下储存规范：

• 避免**反复冻融**；
• 短期需求（1-2周）：4°C避光保存；
• 中短期储存（最长12个月）：-20°C避光保存；
• 长期储存：-80°C避光保存。

注意：以上信息可能随着产品优化升级等因素产生变动，具体信息请咨询亚科因公司。

BioSIM anti-Human TNFRSF17/CD269 Antibody (Belantamab Biosimilar), Research Grade

Basic Product Information

• English Name: BioSIM anti-Human TNFRSF17/CD269 Antibody (Belantamab Biosimilar), Research Grade
• Chinese Name: BioSIM anti-Human TNFRSF17/CD269 Antibody (Belantamab Biosimilar), Research Grade
• CAS Number: 2061894-48-0
• Supplier: InvivoCrown
• Catalog Number: SIM0060-5mg
• Size: 5mg
• Product Type: Secondary Antibody

Core Parameters

• Host Source: Humanized
• Reactivity: Human
• Immunogen: Please refer to the product manual

Background and Research Value

This product is a **non-therapeutic Belantamab biosimilar** that shares the variable region with the therapeutic humanized IgG1 monoclonal antibody targeting BCMA/CD269/TNFRSF17, suitable for research applications.

BCMA (Type III membrane glycoprotein) has well-defined expression and functional characteristics:

• Expression Distribution: Expressed on the surface of mature plasma B cells (normal lymphoid tissues) under physiological conditions; highly expressed in multiple myeloma (MM) cells under pathological conditions;
• Molecular Binding: Can bind to APRIL (with higher affinity than BAFF);
• Signaling Regulation: Participates in the NF-κB/JNK-3 pathway, affecting B-cell survival and humoral immune balance.

The therapeutic Belantamab-mafodotin ADC can induce ADCC effects and cancer cell apoptosis. As this product shares the variable region with the therapeutic antibody, it is suitable for basic research on BCMA-related mechanisms and multiple myeloma.

Application Scenarios

This product supports the following research applications:

• ELISA: Detection of BCMA antigen or antibody binding activity in samples;
• FACS: Analysis of BCMA expression levels and distribution characteristics on cell surfaces;
• Functional assay: Evaluation of functional effects after antibody binding to BCMA;
• Research in vivo: BCMA-related mechanism studies at the animal model level (requires appropriate research design).

Storage Recommendations

To ensure product stability, please follow the following storage guidelines:

• Avoid **repeated freeze-thaw cycles**;
• Short-term storage (1-2 weeks): Store at 4°C protected from light;
• Medium-term storage (up to 12 months): Store at -20°C protected from light;
• Long-term storage: Store at -80°C protected from light.

Note: The above information may be subject to change due to product optimization and upgrades. For specific information, please contact InvivoCrown.